AI-Driven Innovation in Clinical Trials: Veeda Lifesciences Partners with Mango Sciences

In a significant move to enhance clinical trial efficiency and diversity, Indian contract research organization (CRO) Veeda Lifesciences has announced a strategic investment in Boston-based health tech firm Mango Sciences. This partnership grants Veeda access to Mango's advanced generative AI platform, Querent, marking a pivotal step in the integration of artificial intelligence into oncology drug development.

Veeda's AI-Powered Transformation

Veeda Lifesciences, recently rebranded from its previous identity, is set to leverage Mango's Querent platform to streamline clinical trial procedures, improve data management, and increase the diversity of research participants. The collaboration aims to automate patient identification for clinical trials and expand Veeda's presence in the European market.

Dr. Mahesh Bhalgat, Managing Director and CEO of Veeda, emphasized the transformative nature of this partnership: "Our partnership will transform Veeda into an AI-driven oncology drug development organization, meeting the growing demand for diversity in clinical trials, which is in line with the expectations of regulators and pharmaceutical companies. We will be one of only a few CROs focused in oncology with access to this proprietary technology."

Mango Sciences' AI Innovation

Mango Sciences, founded in 2020, has been at the forefront of incorporating large language models and generative AI into its Querent platform. Dr. Mohit Misra, founder and CEO of Mango, highlighted the company's ultimate goal: "identifying the right drug for the right patient."

The Boston-based firm, formerly known as Enlightiks, has a history of innovation in healthcare analytics. Its acquisition by Practo Technologies in 2016 and subsequent rebranding as Mango Sciences in 2020 set the stage for its current focus on AI-driven healthcare solutions.

Veeda's Global Expansion

This partnership with Mango Sciences is part of Veeda's broader strategy for global expansion. Earlier this year, Veeda underwent a rebranding, changing its name to Veeda Lifesciences and introducing a new infinity-inspired logo to reflect its expanding CRO and CDMO services.

The company's growth trajectory was further bolstered by its acquisition of European CRO Heads in March 2024, which added 25 locations across North America, Europe, and the Asia-Pacific region to Veeda's global footprint. This expansion, coupled with the new AI capabilities from Mango Sciences, positions Veeda as a formidable player in the evolving landscape of clinical research and drug development.